Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.

[1]  S. Bonner-Weir,et al.  Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies , 2014, Diabetes, obesity & metabolism.

[2]  M. Nauck,et al.  Risk of pancreatitis in patients treated with incretin-based therapies , 2014, Diabetologia.

[3]  B. Hummer,et al.  Pancreatic safety of incretin-based drugs--FDA and EMA assessment. , 2014, The New England journal of medicine.

[4]  J. Holst,et al.  Insulin Resistance Alters Islet Morphology in Nondiabetic Humans , 2014, Diabetes.

[5]  M. Monami,et al.  Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. , 2014, Diabetes research and clinical practice.

[6]  M. Monami,et al.  Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.

[7]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[8]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[9]  Livio Luzi,et al.  Energy Expenditure Evaluation in Humans and Non-Human Primates by SenseWear Armband. Validation of Energy Expenditure Evaluation by SenseWear Armband by Direct Comparison with Indirect Calorimetry , 2013, PloS one.

[10]  J. Skyler,et al.  An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. , 2013, Diabetes technology & therapeutics.

[11]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[12]  M. Nauck.  A Critical Analysis of the Clinical Use of Incretin-Based Therapies , 2013, Diabetes Care.

[13]  M. Atkinson,et al.  Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors , 2013, Diabetes.

[14]  R. DeFronzo,et al.  IMPACT OF OBESITY SEVERITY AND DURATION ON PANCREATIC β-AND α-CELLS DYNAMICS IN NORMOGLYCEMIC NON-HUMAN PRIMATES , 2012, International Journal of Obesity.

[15]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[16]  D. Braun,et al.  Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[17]  A. Gastaldelli,et al.  The ontogeny of the endocrine pancreas in the fetal/newborn baboon. , 2012, The Journal of endocrinology.

[18]  S. Dry,et al.  Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras G12D mouse model (Diabetes (2012) 61, (1250-1262)) , 2012 .

[19]  A. E. Jensen,et al.  The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. , 2012, American journal of physiology. Endocrinology and metabolism.

[20]  A. Mølck,et al.  The Human GLP-1 Analog Liraglutide and the Pancreas , 2012, Diabetes.

[21]  S. Dry,et al.  Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model , 2012, Diabetes.

[22]  L. Macconell,et al.  Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials , 2012, Diabetes, metabolic syndrome and obesity : targets and therapy.

[23]  P. Higgins,et al.  Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates , 2011, PloS one.

[24]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[25]  D. Drucker,et al.  The safety of incretin-based therapies--review of the scientific evidence. , 2011, The Journal of clinical endocrinology and metabolism.

[26]  R. Elashoff,et al.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.

[27]  Christopher Holland,et al.  Unbiased Histological Examinations in Toxicological Experiments (or, the Informed Leading the Blinded Examination) , 2011, Toxicologic pathology.

[28]  A. Malapati,et al.  Natural pathology of the Baboon (Papio spp.) , 2011, Journal of medical primatology.

[29]  B. Gedulin,et al.  Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. , 2010, American journal of physiology. Endocrinology and metabolism.

[30]  C. Alexander,et al.  Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes , 2010, Diabetes, obesity & metabolism.

[31]  M. Pendergrass,et al.  Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin , 2010, Diabetes Care.

[32]  D. Drucker,et al.  Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits , 2010, Diabetes Care.

[33]  A. Chavez,et al.  Spontaneous pathology of the baboon endocrine system , 2009, Journal of medical primatology.

[34]  R. DeFronzo,et al.  Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons , 2009, Proceedings of the National Academy of Sciences.

[35]  S. Dry,et al.  Beneficial Endocrine but adverse Exocrine effects of Sitagliptin in the HIP rat model of Type 2 Diabetes, interactions with Metformin. , 2009 .

[36]  S. Dry,et al.  but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. , 2009 .

[37]  D. Bulchandani,et al.  Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas , 2009, Diabetologia.

[38]  T. Aye,et al.  Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. , 2008, Biochemical Society transactions.

[39]  R. DeFronzo,et al.  Physiological and Molecular Determinants of Insulin Action in the Baboon , 2008, Diabetes.

[40]  J. Leahy.  Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes , 2008 .

[41]  John Baillie,et al.  AGA Institute technical review on acute pancreatitis. , 2007, Gastroenterology.

[42]  C. Mandarim-de-Lacerda.  Erratum to "Stereological tools in biomedical research"[An Acad Bras Cienc 75(2003): 469-486] , 2007 .

[43]  Michio Shimizu,et al.  An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms , 2004, The American journal of surgical pathology.

[44]  C. Mandarim-de-Lacerda,et al.  Stereological tools in biomedical research. , 2003, Anais da Academia Brasileira de Ciencias.

[45]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[46]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[47]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[48]  R. Perfetti,et al.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. , 2002, Endocrinology.

[49]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[50]  C. Wright,et al.  Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. , 2001, Diabetes.

[51]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[52]  K. Carey,et al.  A social tethering system for nonhuman primates used in laboratory research. , 1990, Laboratory animal science.

[53]  H. McClure,et al.  A Survey of Pancreatic Lesions in Nonhuman Primates , 1982, Veterinary pathology. Supplement.